WuXi AppTec

Third Quarterly 2025 Results

October 27, 2025

603259.SH / 2359.HK

Forward-Looking Statements

This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor a undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. **ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES.** All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this presentation to reflect future events or circumstances, except as required under applicable law.

Continuing Operations and Discontinued Operations

In accordance with IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the first three quarters of 2025 or the comparison year as discontinued operations (“Discontinued Operations”). The remaining operations of the Company will continue to be reported as continuing operations (“Continuing Operations”).

Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, foreign exchange-related gains or losses, amortization of acquired intangible assets from merger and acquisition, gains or losses from divestiture, restructuring and resource integration initiatives, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRSs.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRSs. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRSs, or as being comparable to results reported or forecasted by other companies.

Intellectual Property

Disclaimer

This presentation is for information purposes only and does not constitute a recommendation regarding any securities of the Company. This presentation does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For relevant information, please refer to the Company’s disclosure documents and information on the Shanghai Stock Exchange (“SSE”), the Stock Exchange of Hong Kong Limited (“HKEX”) and the Company’s website.

01 Results Overview

02 Segment Performance

03 Financial Performance

04 Company Outlook

Note: Unless otherwise stated, all financials disclosed in this presentation are prepared based on IFRSs. The currency is RMB.
All net profit disclosed in this presentation represents net profit attributable to the owners of the Company.

1. Results Overview

Q1-Q3 2025 Revenue & Profit Achieved Strong Growth; Revenue from Continuing Operations Up 22.5% YoY, and Adjusted Non-IFRS Net Profit Up 43.4% YoY

Revenue



Adjusted Non-IFRS Net Profit



Note: 1. YoY revenue growth rate from Continuing Operations.

With Continuous Capacity Expansion to Better Meet Customer Demand, Backlog for Continuing Operations[1] Up 41.2% YoY as of September 30, 2025

Backlog for Continuing Operations[1]



Note: 1. As disclosed in 2025 Third Quarterly Report, Continuing Operations include WuXi Chemistry, WuXi Testing, WuXi Biology and Others, the scope of which may change following adjustments to the Company's business strategy.

Diversified Revenue Streams of Continuing Operations from Customers Across Regions Ensure the Stability and Resilience of the Company’s Financial Performance

RMB billion

US

22.15Bn, +31.9%

Revenue contribution: 68%

Europe

3.84Bn, +13.5%

Revenue contribution: 12%

China

5.04Bn, +0.5%

Revenue contribution: 16%

Japan, Korea & Others

1.42Bn, +9.2%

Revenue contribution: 4%

Note: Revenue by region is presented based on the country/region of domicile of customers’ parent company. Geographical affiliations of customers may change in case of M&A, spin-offs and etc., and thus revenue by region has been adjusted accordingly (similar to the 2024 baseline).

2. Segment Performance

WuXi Chemistry: CRDMO Business Model Drives Continuous Growth, Q1-Q3 2025 Revenue Up 29.3% YoY, with TIDES Revenue Up 121.1% YoY

Revenue & Gross Profit Margin



CRDMO Business Model Drives Continuous Growth

- WuXi Chemistry Q1-Q3 revenue up **29.3%** YoY to **25.98bn**
- With continued optimization of production process and improvement in capacity efficiency driven by the growth of late-stage clinical and commercial projects, WuXi Chemistry Q1-Q3 adjusted non-IFRS GPM steadily improved **5.8pts** YoY to **51.3%**

Small Molecule Drug Discovery (R) Continues to Generate Downstream Opportunities

- In the past 12 months, successfully synthesized and delivered **430,000+** new compounds
- In Q1-Q3, **250** molecules converted from R to D

Small Molecule Development and Manufacturing (D&M) Remains Strong

- Small molecule CDMO pipeline **continued to expand**; Q1-Q3 small molecule D&M revenue up **14.1%** YoY to **14.24bn**
- Continued to build small molecule capacity. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with **no single observation**; total reactor volume of small molecule APIs is expected to reach **>4,000kL** by end of 2025

New Modalities (TIDES) Sustains Rapid Growth

- With the ramp-up of new capacity released sequentially each quarter last year, Q1-Q3 TIDES revenue grew **121.1%** YoY to **7.84bn**. By end of September 2025, TIDES backlog up **17.1%** YoY
- TIDES D&M customers grew **12%** YoY, and molecules grew **34%** YoY
- In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule; the Company’s total reactor volume of Solid Phase Peptide Synthesizers has been increased to **>100,000L**

WuXi Chemistry: Driven by "Follow the Molecule + Win the Molecule", Small Molecule CRDMO Pipeline Efficiently Converts and Captures High-Quality Molecules, Delivering Sustained Growth

"R" 5%↓

"D" 2%↑

"M" 18%↑

Q1-Q3 2025 Newly Added Molecules to D&M Pipeline in Total **621**

Including **250** Molecules Converted from R to D



+15

Commercial & Phase III Projects (in Q1-Q3 2025)

WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leading Positions

Revenue & Gross Profit Margin



Lab Testing Services

- With development of differentiated capabilities and enhanced operational management, Q3 revenue of lab testing services reached **1.08bn**, up **7.2%** YoY and **7.5%** QoQ; Q3 adjusted non-IFRS GPM **continued to improve** QoQ. Of which, drug safety evaluation services revenue up **5.9%** YoY and **13.2%** QoQ
- Q1-Q3 revenue of lab testing services up **2.7%** YoY to **2.96bn**. Due to market impact, Q1-Q3 adjusted non-IFRS GPM declined as pricing gradually reflected in revenue along with backlog conversion. Of which, drug safety evaluation service revenue **resumed positive YoY growth**, while maintaining **industry leading** position in APAC
- Actively enabling customers' global licensing. **New modality business continued to develop**, while maintaining leading position in areas including nucleic acids, conjugates, mRNA, multispecific antibodies and peptides
- **Continued to advance automation**. DMPK successfully launched its proprietary all-in-one compound identification software, enhancing efficiency in spectral interpretation and metabolite identification for nucleic acids and peptides by **83%**
- Suzhou facility has successfully passed **4 consecutive** FDA on-site inspections

Clinical CRO & SMO

- Q1-Q3 revenue of clinical CRO and SMO down **6.4%** YoY to **1.21bn** due to market pricing impact. Of which, SMO revenue down **0.7%** YoY as backlog gradually converted into revenue, while maintaining **industry leading** position in China
- In Q1-Q3, clinical CRO supported customers to obtain **19** IND approvals and submit for **2** NDA filings; SMO supported **75** new drug approvals. SMO has supported **331** new drug approvals in total over the past decade, maintaining significant advantages in multiple areas (endocrinology, dermatology, lung cancer and cardiovascular disease, etc.)

WuXi Biology: Continues to Generate Downstream Opportunities; *In Vitro & In Vivo* Business Synergies and New Modality Business Drive Growth



- Follow the science, continuously strengthen drug discovery capabilities in emerging areas and actively grow overseas businesses. WuXi Biology **efficiently generates downstream opportunities for CRDMO model** by continuously contributing **20%+** of the Company's new customers
- Through cross-regional collaboration, comprehensive platform integration and integrated project transformation, efficiently enable customers worldwide. WuXi Biology Q1-Q3 revenue up **6.6%** YoY to **1.95bn**
- Due to market pricing impact, WuXi Biology Q1-Q3 adjusted non-IFRS GPM down **1.0pts** YoY to **37.0%**. With continuously improved operational efficiency, Q3 adjusted non-IFRS GPM improved by **1.5pts** QoQ
- **Accelerated advancements in *in vitro* integrated screening technologies and continued to improve *in vivo* pharmacology capabilities**, resulting in rapid YoY and QoQ revenue growth. With its competitive edge continuously strengthened, and the non-oncology business has achieved strong revenue growth, becoming an important contributor to business growth
- **New modality drug discovery services continue to perform well**, contributing **30%+** of WuXi Biology's total revenue

3. Financial Performance

Continuously Strengthen Technological Expertise and Operating Efficiency, Leverage Management Resilience, Further Enhancing Profitability

Adjusted Non-IFRS Gross Profit

Adjusted Non-IFRS GPM*

RMB billion



* GPM @ CER[1]: Q1-Q3 2024 41.6%， Q1-Q3 2025 47.2%

Adjusted Non-IFRS Net Profit

Adjusted Non-IFRS NPM

RMB billion



Net Profit After Deducting Non-Recurring Items (per CAS[2])

RMB billion



Net Profit (per CAS[2])

RMB billion



 Note: 1. CER, constant exchange rate. 2. CAS, China Accounting Standards for Business Enterprises.

With Continued Business Growth, Efficient Operations and Constant Improvement of Financial Management Capabilities, Q1-Q3 2025 Operating Cash Flow Up 35.0% YoY to 10.87 Billion



Note: 1. Capex includes purchase of property, plant and equipment, other intangible assets and other long-term expenses.

4. Company Outlook

Continue to Focus on CRDMO Business Model, and Accelerate Growth of Global Capabilities and Capacities

- To further **focus and strengthen our core CRDMO business and invest to accelerate growth of global capabilities and capacities, by concentrating on drug discovery, laboratory testing, process development and manufacturing services**, the Company signed an agreement on October 24th, 2025, with Hillhouse Investment Management, to sell 100% equity of its China-based clinical research services business, including Clinical CRO and SMO.

- The transaction has not yet been completed, and its completion is still subject to all mandatory government approvals/filings by all parties.

- The aforementioned business will be classified as Discontinued Operations in the Company's 2025 Annual Report, collectively contributing 3.5% and 0.7% of the Company's total revenue and total net profit[1] in Q1-Q3 2025, respectively. The gain from the completion of this transaction is expected to exceed 10% of the Company's audited net profit for the most recent fiscal year, and therefore has been submitted to and approved by the Company's Board of Directors.

- For more details, please refer to the Company's announcement.

Note: 1. Net profit per CAS (China Accounting Standards for Business Enterprises).

Company Outlook

Focus on the CRDMO business model, striving for highly efficient & exceptional services and lean operations ("O")

- Continue to **focus** on our unique integrated **CRDMO** core business, and **accelerate global expansion, capacity construction and capability development**
- Leveraging customers' **ongoing demand for enabling services**, provide **highly efficient and exceptional services**, benefiting patients worldwide, and driving long-term growth
- Promote **lean management and operations**, continuously improving **production and operational efficiency**, and making every effort to reduce the impact of external uncertainties

With confidence in customers' ongoing demand, our CRDMO business model and management execution, further raised full-year guidance

- **Continuing Operations revenue** expects to resume double-digit growth in 2025, with its **YoY growth rate raised to 17-18%**, up from the prior 13-17%; targeting full-year **total revenue of RMB43.5-44.0 billion**, up from the prior RMB42.5-43.5 billion
- Focus on core CRDMO business and continuously improved production and operating efficiency; confident to **further improve adjusted non-IFRS NPM** in 2025
- The Company is actively advancing global capacity construction; while due to longer-than-expected settlement cycles of certain projects, capex for 2025 is expected to reach RMB5.5-6.0 billion (adjusted from the prior RMB7.0-8.0 billion). Together with business growth, efficiency improvement, and considering the timing differences in project payments, **free cash flow** for 2025 is expected to **increase** from RMB5.0-6.0 billion to **RMB8.0-8.5 billion**

Company Outlook

Remain committed to rewarding shareholders and upholding the Company's value

- This year, the Company has **implemented a total of RMB6.88 billion in cash dividends, share repurchases and cancellations**, representing 70%+ of the Company's net profit[1] in 2024:
  - distributed **a total of RMB4.88 billion in cash dividends**, including RMB2.83 billion for 2024 annual cash dividend, RMB1.01 billion for 2025 special cash dividend and RMB1.03 billion for 2025 interim dividend
  - completed the **repurchase of RMB2.0 billion** worth of **A-shares** in total, **all of which have been cancelled**

Retain top talents and enhance the resilience of business operations and management

- This year, the Company has **completed the acquisition of HKD2.5 billion** worth of **H-shares** for the purpose of the 2025 H-share Incentive Trust Plan. This aims **to continuously attract and retain top talents, strengthen the collective capabilities of management team, and enhance the resilience of the Company's business operations and management**, and there will be **no dilution to existing shareholders**
- According to the plan approved by the Annual General Meeting, upon achieving RMB42.0 billion revenue, no more than HKD1.5 billion H-shares will be granted; and an additional HKD1.0 billion H-shares will be granted upon reaching RMB43.0 billion and above in revenue

 Note: 1. Net profit per CAS (China Accounting Standards for Business Enterprises).